Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin

Michael Lilly, Chris Tompkins, Chris Brown, George Pettit, Andrew Kraft

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We have examined the ability of bryostatin 1 (bryo), an activator of protein kinase C, to induce differentiation of chronic myelogenous leukemia (CML) cells obtained from peripheral blood. Bryo induced a prompt and persistent macrophage-like differentiation, as evidenced by functional, morphological, and immunological criteria. Differentiated cells remained viable for at least 21 days with little change in cell number. CML cell cultures treated in semisolid medium with bryo showed diffuse infiltration with single macrophages, as well as discrete macrophage, mixed, and granulocytic colonies. Supernatants of suspension cultures of bryo-treated CML cells contained granulocyte-macrophage colony-stimulating factor (GM-CSF) by enzyme-linked immunosorbent assay. Furthermore, colony formation could be significantly inhibited by the addition of antibodies to GM-CSF. Prolonged liquid culture of CML cells in bryo reduced colony-forming unit, granulocyte-macrophage content. Bryo-induced differentiation was associated with a decrease in lactoferrin, a marker of granulocyte differentiation, and an increase in both c-fms and interleukin-1β RNA, both of which are expressed by monocytes/macrophages. These data demonstrate that bryostatin 1 is capable of inducing macrophage-like differentiation in maturing CML cells. Furthermore, bryostatin induces secretion of GM-CSF by such cells in suspension and semisolid medium and also promotes clonal extinction of granulocytemacrophage progenitors. Bryostatin may be a possible therapeutic agent for CML.

Original languageEnglish (US)
Pages (from-to)5520-5525
Number of pages6
JournalCancer Research
Volume50
Issue number17
StatePublished - Sep 1 1990

Fingerprint

Bryostatins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Macrophages
Granulocyte-Macrophage Colony-Stimulating Factor
Growth
Suspensions
Granulocyte-Macrophage Progenitor Cells
Lactoferrin
Differentiation Antigens
Interleukin-1
Granulocytes
Protein Kinase C
Monocytes
Cell Culture Techniques
Cell Count
Enzyme-Linked Immunosorbent Assay
bryostatin 1
RNA
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lilly, M., Tompkins, C., Brown, C., Pettit, G., & Kraft, A. (1990). Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Research, 50(17), 5520-5525.

Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. / Lilly, Michael; Tompkins, Chris; Brown, Chris; Pettit, George; Kraft, Andrew.

In: Cancer Research, Vol. 50, No. 17, 01.09.1990, p. 5520-5525.

Research output: Contribution to journalArticle

Lilly, M, Tompkins, C, Brown, C, Pettit, G & Kraft, A 1990, 'Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin', Cancer Research, vol. 50, no. 17, pp. 5520-5525.
Lilly, Michael ; Tompkins, Chris ; Brown, Chris ; Pettit, George ; Kraft, Andrew. / Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. In: Cancer Research. 1990 ; Vol. 50, No. 17. pp. 5520-5525.
@article{10da00bb0436463481408701d3375789,
title = "Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin",
abstract = "We have examined the ability of bryostatin 1 (bryo), an activator of protein kinase C, to induce differentiation of chronic myelogenous leukemia (CML) cells obtained from peripheral blood. Bryo induced a prompt and persistent macrophage-like differentiation, as evidenced by functional, morphological, and immunological criteria. Differentiated cells remained viable for at least 21 days with little change in cell number. CML cell cultures treated in semisolid medium with bryo showed diffuse infiltration with single macrophages, as well as discrete macrophage, mixed, and granulocytic colonies. Supernatants of suspension cultures of bryo-treated CML cells contained granulocyte-macrophage colony-stimulating factor (GM-CSF) by enzyme-linked immunosorbent assay. Furthermore, colony formation could be significantly inhibited by the addition of antibodies to GM-CSF. Prolonged liquid culture of CML cells in bryo reduced colony-forming unit, granulocyte-macrophage content. Bryo-induced differentiation was associated with a decrease in lactoferrin, a marker of granulocyte differentiation, and an increase in both c-fms and interleukin-1β RNA, both of which are expressed by monocytes/macrophages. These data demonstrate that bryostatin 1 is capable of inducing macrophage-like differentiation in maturing CML cells. Furthermore, bryostatin induces secretion of GM-CSF by such cells in suspension and semisolid medium and also promotes clonal extinction of granulocytemacrophage progenitors. Bryostatin may be a possible therapeutic agent for CML.",
author = "Michael Lilly and Chris Tompkins and Chris Brown and George Pettit and Andrew Kraft",
year = "1990",
month = "9",
day = "1",
language = "English (US)",
volume = "50",
pages = "5520--5525",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin

AU - Lilly, Michael

AU - Tompkins, Chris

AU - Brown, Chris

AU - Pettit, George

AU - Kraft, Andrew

PY - 1990/9/1

Y1 - 1990/9/1

N2 - We have examined the ability of bryostatin 1 (bryo), an activator of protein kinase C, to induce differentiation of chronic myelogenous leukemia (CML) cells obtained from peripheral blood. Bryo induced a prompt and persistent macrophage-like differentiation, as evidenced by functional, morphological, and immunological criteria. Differentiated cells remained viable for at least 21 days with little change in cell number. CML cell cultures treated in semisolid medium with bryo showed diffuse infiltration with single macrophages, as well as discrete macrophage, mixed, and granulocytic colonies. Supernatants of suspension cultures of bryo-treated CML cells contained granulocyte-macrophage colony-stimulating factor (GM-CSF) by enzyme-linked immunosorbent assay. Furthermore, colony formation could be significantly inhibited by the addition of antibodies to GM-CSF. Prolonged liquid culture of CML cells in bryo reduced colony-forming unit, granulocyte-macrophage content. Bryo-induced differentiation was associated with a decrease in lactoferrin, a marker of granulocyte differentiation, and an increase in both c-fms and interleukin-1β RNA, both of which are expressed by monocytes/macrophages. These data demonstrate that bryostatin 1 is capable of inducing macrophage-like differentiation in maturing CML cells. Furthermore, bryostatin induces secretion of GM-CSF by such cells in suspension and semisolid medium and also promotes clonal extinction of granulocytemacrophage progenitors. Bryostatin may be a possible therapeutic agent for CML.

AB - We have examined the ability of bryostatin 1 (bryo), an activator of protein kinase C, to induce differentiation of chronic myelogenous leukemia (CML) cells obtained from peripheral blood. Bryo induced a prompt and persistent macrophage-like differentiation, as evidenced by functional, morphological, and immunological criteria. Differentiated cells remained viable for at least 21 days with little change in cell number. CML cell cultures treated in semisolid medium with bryo showed diffuse infiltration with single macrophages, as well as discrete macrophage, mixed, and granulocytic colonies. Supernatants of suspension cultures of bryo-treated CML cells contained granulocyte-macrophage colony-stimulating factor (GM-CSF) by enzyme-linked immunosorbent assay. Furthermore, colony formation could be significantly inhibited by the addition of antibodies to GM-CSF. Prolonged liquid culture of CML cells in bryo reduced colony-forming unit, granulocyte-macrophage content. Bryo-induced differentiation was associated with a decrease in lactoferrin, a marker of granulocyte differentiation, and an increase in both c-fms and interleukin-1β RNA, both of which are expressed by monocytes/macrophages. These data demonstrate that bryostatin 1 is capable of inducing macrophage-like differentiation in maturing CML cells. Furthermore, bryostatin induces secretion of GM-CSF by such cells in suspension and semisolid medium and also promotes clonal extinction of granulocytemacrophage progenitors. Bryostatin may be a possible therapeutic agent for CML.

UR - http://www.scopus.com/inward/record.url?scp=0025074981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025074981&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 5520

EP - 5525

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 17

ER -